5K3Y

Crystal structure of AuroraB/INCENP in complex with BI 811283


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.6 Å
  • R-Value Free: 0.201 
  • R-Value Work: 0.180 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.

Sini, P.Gurtler, U.Zahn, S.K.Baumann, C.Rudolph, D.Baumgartinger, R.Strauss, E.Haslinger, C.Tontsch-Grunt, U.Waizenegger, I.C.Solca, F.Bader, G.Zoephel, A.Treu, M.Reiser, U.Garin-Chesa, P.Boehmelt, G.Kraut, N.Quant, J.Adolf, G.R.

(2016) Mol.Cancer Ther. 15: 2388-2398

  • DOI: 10.1158/1535-7163.MCT-16-0066
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Although the MAPK pathway is frequently deregulated in cancer, inhibitors targeting RAF or MEK have so far shown clinical activity only in BRAF- and NRAS-mutant melanoma. Improvements in efficacy may be possible by combining inhibition of mitogenic s ...

    Although the MAPK pathway is frequently deregulated in cancer, inhibitors targeting RAF or MEK have so far shown clinical activity only in BRAF- and NRAS-mutant melanoma. Improvements in efficacy may be possible by combining inhibition of mitogenic signal transduction with inhibition of cell-cycle progression. We have studied the preclinical pharmacology of BI 847325, an ATP-competitive dual inhibitor of MEK and Aurora kinases. Potent inhibition of MEK1/2 and Aurora A/B kinases by BI 847325 was demonstrated in enzymatic and cellular assays. Equipotent effects were observed in BRAF-mutant cells, whereas in KRAS-mutant cells, MEK inhibition required higher concentrations than Aurora kinase inhibition. Daily oral administration of BI 847325 at 10 mg/kg showed efficacy in both BRAF- and KRAS-mutant xenograft models. Biomarker analysis suggested that this effect was primarily due to inhibition of MEK in BRAF-mutant models but of Aurora kinase in KRAS-mutant models. Inhibition of both MEK and Aurora kinase in KRAS-mutant tumors was observed when BI 847325 was administered once weekly at 70 mg/kg. Our studies indicate that BI 847325 is effective in in vitro and in vivo models of cancers with BRAF and KRAS mutation. These preclinical data are discussed in the light of the results of a recently completed clinical phase I trial assessing safety, tolerability, pharmacokinetics, and efficacy of BI 847325 in patients with cancer. Mol Cancer Ther; 15(10); 2388-98. ©2016 AACR.


    Organizational Affiliation

    Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. patrizia.sini@boehringer-ingelheim.com.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Aurora kinase B-A
A, B
280Xenopus laevisMutation(s): 0 
Gene Names: aurkb-a (airk2-a)
EC: 2.7.11.1
Find proteins for Q6DE08 (Xenopus laevis)
Go to UniProtKB:  Q6DE08
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Inner centromere protein A
C, D
59Xenopus laevisMutation(s): 0 
Gene Names: incenp-a
Find proteins for O13024 (Xenopus laevis)
Go to UniProtKB:  O13024
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
TPO
Query on TPO

Download SDF File 
Download CCD File 
A, B
PHOSPHOTHREONINE
PHOSPHONOTHREONINE
C4 H10 N O6 P
USRGIUJOYOXOQJ-GBXIJSLDSA-N
 Ligand Interaction
6Q4
Query on 6Q4

Download SDF File 
Download CCD File 
A, B
N-methyl-N-(1-methylpiperidin-4-yl)-4-{[4-({(1R,2S)-2-[(propan-2-yl)carbamoyl]cyclopentyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}benzamide
C28 H38 F3 N7 O2
JYFHHSWWLYUOIG-JTHBVZDNSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.6 Å
  • R-Value Free: 0.201 
  • R-Value Work: 0.180 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 45.907α = 90.00
b = 67.295β = 96.19
c = 116.618γ = 90.00
Software Package:
Software NamePurpose
BUSTER-TNTrefinement
SCALAdata scaling
PDB_EXTRACTdata extraction
MOSFLMdata processing
MOLREPphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2016-08-17
    Type: Initial release
  • Version 1.1: 2016-10-19
    Type: Database references